30 September 2026
Epithalon: The 28% Mortality Claim Wasn't Epithalon
The famous 28% mortality figure in epithalon research came from Epithalamin, a bovine pineal extract. What the epitalon evidence actually shows, plus Australia's status.
Peptides · Longevity & Cellular Health
Epithalon
Epitalon · AEDG peptide
Unapproved · evidence unreplicated
A four-amino-acid peptide at the heart of the boldest claim in the peptide world — that it activates telomerase and extends lifespan. The claim rests on decades of work from largely one Russian research group and has never been replicated to modern trial standards.
At a glance
- Telomerase-activation claim originates in cell-culture studies
- Rodent and observational human data from mainly one research group
- No independent modern randomised trials
- Approved nowhere as a medicine
How it works
Epithalon is proposed to stimulate telomerase, the enzyme that rebuilds the protective telomere caps on chromosomes, and to normalise melatonin secretion via the pineal gland. Both mechanisms are drawn from cell culture and animal studies.
What the research shows
The supporting literature — telomere elongation in cultured cells, lifespan extension in rodents, and long-term observational data in elderly Russian cohorts — comes overwhelmingly from the Khavinson group in St Petersburg. No independent, modern randomised trial has confirmed the anti-aging claims.
Regulatory status
Australia
Not an approved medicine in Australia and not ARTG-listed.
Worldwide
Not approved by any major regulator. It has never been submitted through FDA or EMA trial pathways.
Latest Epithalon articles
27 September 2026
Epithalon Research: The Only Independent Study Got Corrected
Epithalon's only independent human-cell study was corrected in Nov 2025. What the Brunel paper did, the missing dose curve, and epithalon's Australian status.
24 September 2026
Epithalon Research: The Retina Dish, Not the Telomere
The newest epithalon research isn't about telomeres — it's retinal cells in a dish. What it showed, and where epithalon legally sits in Australia in 2026.
22 September 2026
Is Epithalon Proven in Humans? The 266-Patient Swap
The famous 266-patient human study behind epithalon used Epithalamin, a bovine pineal extract, not the synthetic peptide. What epithalon research actually shows.
19 September 2026
Epithalon Research: The Replication That Got a Correction
The only independent epithalon study was corrected in November 2025. What changed, what didn't, and where epithalon research stands in Australia in 2026.
16 September 2026
Epithalon Research: The Cancer-Cell Half Nobody Quotes
Epithalon research: the 2025 Brunel study lengthened telomeres in normal human cells — and in two breast cancer lines via ALT. Plus its Australian status.
13 September 2026
Epithalon Dosing: The Pharmacokinetics Nobody Measured
Epithalon research has no published human pharmacokinetic study. What that means for dosing claims, the 2025 independent lab data and epithalon in Australia.
11 September 2026
Epithalon vs Epithalamin: The 28% Claim Explained
Is epithalon legal in Australia, and does the famous 28% mortality figure even apply? We separate synthetic epitalon from Epithalamin and check the evidence.
28 August 2026
Epithalon Research: The Telomere Result That Isn't Telomerase
Is epithalon legal in Australia, and what does epitalon research show? A 2025 human-cell study found telomere growth - but maybe not via telomerase.
27 August 2026
Epithalon (Epitalon): Telomere Claims vs the Evidence
Epithalon (epitalon) is sold as a longevity peptide that lengthens telomeres. We look at what the research actually shows and its Australian status.
This is general information, not medical advice. retatrutide.net.au is an independent publication. Unless stated otherwise above, this compound is not an approved medicine in Australia, and this page does not endorse or facilitate its use. Speak to a registered health practitioner about any treatment decision.
Stay informed
Be first to know.
When it reaches Australia.
Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:
- The latest clinical trial results and news from Eli Lilly
- Updates on TGA regulatory progress in Australia
- How and where to access Retatrutide when it becomes available
- Occasional information from retatrutide.net.au and our affiliated partners
TGA review expected 2027 — subscribers hear the moment the status changes.
Get the free guide + updates
Enter your details once on our free access guide page — instant download, plus we'll email you the moment there's real news.